Despite important reductions in nonfatal MI, aspirin prophylaxis in people without prior CVD does not lead to reductions in either cardiovascular death or cancer mortality. Because the benefits are further offset by clinically important bleeding events, routine use of aspirin for primary prevention is not warranted and treatment decisions need to be considered on a case-by-case basis. (Ver)Parece que las dudas planteadas en su momento...se confirman.
Ver
Entradas
No hay comentarios:
Publicar un comentario